Trial Profile
Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Adverse reactions
- Acronyms ELPIS; ELPIS I
- Sponsors Longeveron
- 13 Nov 2023 Results assessing long-term transplant-free survival, presented at the American Heart Association Scientific Sessions 2023.
- 02 Oct 2023 Planned primary completion date changed from 1 Feb 2021 to 30 Jun 2024.
- 07 Sep 2023 According to Longeveron media release, abstract accepted for poster presentation which will be presented at the Scientific Sessions of the American Heart Association, to be held in Philadelphia, PA, November 11-13, 2023.